US Patent 10,383,884: Omadacycline CABP Dosing Claims, Scope, Expiration and Generic Risk

US Patent 10,383,884 protects specific intravenous-to-oral omadacycline dosing regimens for treating community-acquired bacterial pneumonia (CABP). The patent does not broadly claim omadacycline, its tosylate salt, or every use of Nuzyra. Its principal protection is narrower: a defined sequence of 100-mg intravenous doses followed by once-daily intravenous dosing, with optional transition to 300-mg oral dosing. The patent was assigned to Paratek Pharmaceuticals and covers treatment methods rather than the active compound itself.[1]

The patent is commercially relevant because its claims correspond closely to the clinical dosing and IV-to-oral treatment strategy used for Nuzyra (omadacycline). The Orange Book-listed patent term is reported to run through June 7, 2032.[2] FDA approval for CABP was granted in 2018, and FDA regulatory exclusivity has expired.[3]

What drug and treatment method does US 10,383,884 protect?

The patent protects use of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline, the chemical name for omadacycline, or a salt thereof, in CABP patients.

The central regimen is:

Treatment stage	Claimed dose	Timing
Initial IV loading	100 mg IV	Three doses, 12 hours apart
Continued IV treatment	100 mg IV	Every 24 hours after the third loading dose
Optional oral transition	300 mg orally	12-24 hours after the last IV dose
Continued oral treatment	300 mg orally	Every 24 hours

The claims cover treatment of a human subject, although the core independent claims use the broader term “subject.” The active ingredient may be administered as omadacycline or a salt, with claim 18 narrowing the salt to the tosylate salt.

The patent therefore targets a complete therapeutic regimen rather than a single dose, formulation, or manufacturing process.

How do the independent claims of US 10,383,884 differ?

Claims 1, 2 and 4 define three related regimen structures.

Claim 1: IV treatment with optional oral step-down

Claim 1 requires:

Three 100-mg IV doses administered 12 hours apart.
One or more 100-mg IV doses administered every 24 hours.
An optional 300-mg oral dose 12-24 hours after the preceding IV dose.
Optional additional 300-mg oral doses every 24 hours.

The use of “comprising” gives claim 1 an open transitional structure. A regimen may satisfy the claim even if it contains additional treatment elements, provided the required sequence is performed.

The oral dosing portion is expressly optional. A treatment course can infringe claim 1 through the IV sequence alone, assuming the other limitations are met.

Claim 2: IV-to-oral treatment with mandatory oral dosing

Claim 2 requires the same initial IV sequence but makes the oral portion mandatory. It requires one or more 300-mg oral doses every 24 hours after the relevant IV dosing.

Claim 2 is narrower than claim 1 because it requires oral treatment. It is directed to IV-to-oral step-down therapy rather than IV-only therapy.

Claim 4: IV-only treatment

Claim 4 covers three 100-mg IV loading doses 12 hours apart followed by one or more 100-mg IV doses every 24 hours.

Unlike claim 1, claim 4 does not include oral administration. It is the principal independent claim for an all-IV CABP course.

What limitations narrow the patent claims?

The dependent claims add clinical, duration, formulation, administration and outcome limitations.

Claim	Limitation
3	Claim 2 regimen with exactly one 100-mg IV dose in the once-daily continuation stage
5	Treatment completed within 7-20 days
6	IV dosing for 3-10, 3-6, 7-10 or 5 days
7	Oral step-down regimen with IV dosing for 4-7, 4-5, 6-7 or 5 days
8	Oral dosing for 1-7, 1-4, 5-7 or 5 days
9	Five days of IV dosing followed by five days of oral dosing
10	CABP caused by specified bacterial pathogens
11	Human subject
12	Each 300-mg oral dose administered as two 150-mg tablets
13	Each IV dose infused continuously over approximately 30 minutes
14	Non-inferiority clinical success compared with moxifloxacin
15	Symptom improvement by days 3-5
16	Symptom and vital-sign improvement by days 3-5
17	Fasting conditions around oral dosing
18	Tosylate salt
19	Defined clinical-success rates measured 72-120 hours after first IV dose
20	PORT Risk Class III or IV CABP
21	Mild gastrointestinal adverse events or no discontinuation due to GI events
22	No increased C. difficile risk or substantial gut-microbiome disruption

Claims 5 through 9 are particularly relevant to a conventional 10-day treatment course. Claim 9 specifies five IV days followed by five oral days, a practical IV-to-oral treatment design.

What pathogens and patient populations are covered?

Claim 10 identifies a broad CABP pathogen set, including:

Methicillin-resistant Staphylococcus aureus (MRSA)
Streptococcus pneumoniae, including penicillin-resistant strains
Haemophilus influenzae
Moraxella catarrhalis
Klebsiella pneumoniae
Legionella pneumophila
Chlamydophila pneumoniae
Mycoplasma pneumoniae
Chlamydophila psittaci
Coxiella burnetii
Escherichia coli
Combinations of the listed organisms

The pathogen limitation appears only in a dependent claim. The independent claims are not limited to one named organism. A CABP treatment regimen can therefore fall within claims 1, 2 or 4 without the treating party knowing or proving that the infection was caused by a specific listed pathogen, subject to the applicable claim-construction and infringement standards.

Claim 20 narrows the population to PORT Risk Class III or IV patients. This corresponds to moderate-to-severe CABP populations commonly used in hospital-based clinical trials.

What formulations and administration methods are protected?

US 10,383,884 contains limited formulation protection. It does not claim the chemical formulation of an IV product or tablet as an independent composition claim.

Its formulation-related protection is functional and administration-specific:

The oral dose is approximately 300 mg.
Claim 12 specifies two 150-mg tablets.
Claim 13 requires continuous IV infusion over approximately 30 minutes.
Claim 17 requires fasting before and after the oral dose, including restrictions on food and dairy products.
Claim 18 covers the tosylate salt.

The FDA label for Nuzyra describes IV administration over approximately 30 minutes and oral administration under fasting conditions. The label also identifies omadacycline tosylate as the active pharmaceutical ingredient.[4]

The patent’s formulation risk is therefore highest where a competing product uses the same active ingredient, oral strength, tablet configuration and IV administration profile. A materially different dose, interval, route, or treatment sequence could reduce exposure under these claims, although other omadacycline patents may remain relevant.

When does US 10,383,884 lose exclusivity?

The Orange Book patent entry for US 10,383,884 reports an expiration date of June 7, 2032.[2]

Milestone	Date or status
Patent grant	August 20, 2019
FDA approval of Nuzyra for ABSSSI and CABP	October 2, 2018
FDA new chemical entity exclusivity	Expired
Reported patent expiration	June 7, 2032
Patent type	Method-of-use patent
Covered product	Nuzyra, omadacycline tosylate

The expiration date does not mean every omadacycline patent expires on the same date. Omadacycline has a broader patent estate that includes compound, composition, formulation, and additional method-of-use patents. A generic applicant must evaluate the full Orange Book listing, not only US 10,383,884.

The patent term also does not establish that generic entry is impossible before 2032. An ANDA applicant may pursue a Paragraph IV certification, prevail in litigation, obtain a settlement-based launch date, or design around particular claim limitations.

What is the Orange Book status of US 10,383,884?

US 10,383,884 is listed in connection with Nuzyra as a method-of-use patent. The listing is directed to treatment of CABP using the claimed omadacycline dosing regimen.

The patent does not by itself block every abbreviated new drug application for omadacycline. Under the Hatch-Waxman framework, the practical effect depends on:

The indications and dosing instructions included in the generic label.
Whether the applicant files a Paragraph IV certification.
Whether the patent holder files an infringement action within the statutory period.
Whether the generic label uses a skinny-label strategy that omits the patented CABP use.
Whether other listed patents cover the active ingredient, product, or remaining indications.

A generic seeking approval only for a non-CABP indication may attempt to omit the patented CABP method. That strategy would not automatically eliminate risk under other listed patents or under an induced-infringement theory based on labeling and marketing conduct.

What Paragraph IV challenges and litigation affect this patent?

A Paragraph IV certification would assert that the patent is invalid, unenforceable, or not infringed. The patent’s method-of-use character creates several possible challenge theories:

The claimed dosing sequence was obvious in view of clinical pharmacology and prior tetracycline dosing data.
The claims lack written description or enablement across the full range of treatment durations and clinical outcomes.
The regimen is anticipated by clinical-trial protocols or published treatment data.
A proposed generic label does not practice the claimed CABP regimen.
The patent is unenforceable because of inequitable conduct or another litigation-specific defense.

The strongest non-infringement position would generally involve a label that omits CABP or does not recommend the claimed IV loading sequence and oral transition. The strongest invalidity arguments would focus on prior clinical protocols, dose-ranging studies, and whether the claimed regimen represents a predictable optimization of known omadacycline dosing.

No patent-specific litigation judgment or final invalidity ruling is established here for US 10,383,884. The absence of a cited final judgment means the patent should be treated as an active enforceable right through its reported expiration date.

How strong is the patent estate for omadacycline?

US 10,383,884 is a meaningful but narrow component of the Nuzyra estate.

Estate layer	Commercial function	Relevance to US 10,383,884
Compound patents	Protect omadacycline molecule and related compounds	Separate from this patent
Salt patents	Protect forms such as omadacycline tosylate	Claim 18 provides limited salt coverage
Composition patents	Protect pharmaceutical compositions	Not the principal subject of this patent
Formulation patents	Protect IV and oral dosage forms	This patent has administration limitations, not broad composition claims
Method-of-use patents	Protect treatment of CABP and other infections	Core category for US 10,383,884
Regimen patents	Protect dose, interval and route sequence	Core commercial value of this patent
Manufacturing patents	Protect synthesis, purification or crystal forms	Not covered by the supplied claims

The patent is strongest against a competitor that copies the complete FDA-aligned regimen: three 100-mg IV doses 12 hours apart, daily IV dosing, and a 300-mg oral step-down course. It is weaker against a product that changes the loading schedule, uses a different maintenance dose, excludes CABP from the label, or avoids the claimed IV-to-oral sequence.

The open “comprising” language increases the potential breadth of the core method claims. The numerous “about” limitations create ordinary claim-construction issues around dose and timing tolerances. A court would likely assess those terms against the specification, prosecution history, clinical practice and expert evidence.

How does Nuzyra compare with moxifloxacin under the patent?

Claim 14 defines clinical performance by reference to moxifloxacin administered as 400 mg IV every 24 hours for at least three days, followed by 400-mg oral doses every 24 hours.

Parameter	Claimed omadacycline regimen	Comparator regimen
Loading phase	100 mg IV every 12 hours for three doses	400 mg IV every 24 hours
Maintenance	100 mg IV every 24 hours	400 mg IV every 24 hours
Oral step-down	300 mg every 24 hours	400 mg every 24 hours
Clinical endpoint	Non-inferiority within 10% or 12.5%	Reference treatment
Therapeutic area	CABP	CABP

Claim 14 is narrower than the core regimen claims because it adds a clinical-success relationship. The patent does not require a competitor to prove the claimed success rate to infringe claim 1 if the dosing and CABP limitations are otherwise met. Conversely, failure to meet the claimed non-inferiority margin may be relevant to claim 14 but would not necessarily defeat the independent regimen claims.

What generic launch risks exist for Nuzyra?

The main generic launch scenarios are:

Full-label launch after patent expiry

A generic applicant may seek CABP and other approved indications, certify to listed patents, and launch after all relevant patents expire or after resolving litigation.

Paragraph IV litigation

A challenger may attack US 10,383,884 and other listed patents. Litigation risk would center on obviousness, anticipation, enablement, written description, infringement and the scope of any proposed label.

Skinny-label launch

A generic could omit CABP from its labeling if the omitted use is legally and commercially separable. This strategy is more difficult if the generic label, promotional materials or distribution practices encourage use of the patented CABP regimen.

Design-around

A competitor could seek a different loading schedule, route, dose, or treatment duration. Such a design-around must be evaluated against the full patent estate because another patent may cover the alternative.

Licensing or settlement

A settlement could establish a permitted generic entry date before June 2032. No settlement terms are identified in the supplied material, and no assumed entry date should be used for valuation.

What is the commercial exposure of the patent?

Nuzyra is an antibacterial product with approved indications for CABP and acute bacterial skin and skin-structure infections. The CABP regimen is commercially important because it supports hospital treatment, IV initiation and oral step-down therapy.[4]

The patent’s revenue exposure depends on the portion of Nuzyra sales attributable to CABP and on whether a generic competitor can obtain an indication that overlaps the patented method. The patent is more commercially valuable than a narrow clinical-outcome claim because the principal independent claims capture the dosing architecture itself.

It does not, however, provide complete product exclusivity. A generic may challenge separate patents, omit the patented indication, or enter with a non-infringing regimen if regulatory and commercial conditions permit.

Key Takeaways

US 10,383,884 is a method-of-treatment patent for omadacycline in CABP.
The core regimen is three 100-mg IV doses 12 hours apart, followed by daily 100-mg IV dosing.
Claims 1 and 2 cover IV-to-oral treatment; claim 4 covers IV-only treatment.
The optional oral regimen uses 300 mg every 24 hours, with claim 12 specifying two 150-mg tablets.
Claim 9 covers five days of IV treatment followed by five days of oral treatment.
Claim 10 identifies a broad list of CABP pathogens, including MRSA and drug-resistant Streptococcus pneumoniae.
Claim 18 narrows the active ingredient to the tosylate salt.
The reported Orange Book expiration date is June 7, 2032.
The patent is narrower than a compound or composition patent but directly targets the Nuzyra dosing strategy.
Generic risk depends on the full omadacycline patent estate, Paragraph IV activity, label scope, litigation and any settlement.
Omadacycline is a small molecule, so biosimilar risk is not applicable. Any follow-on competitor would use the generic-drug pathway rather than the biosimilar pathway.

FAQs About US Patent 10,383,884 and Omadacycline

Is US 10,383,884 a composition-of-matter patent?

No. The supplied claims are method claims directed to treating CABP with a specified omadacycline dosing regimen.

Does the patent cover oral omadacycline by itself?

No. The oral dosing is covered only in the context of the claimed preceding IV regimen. Claim 1 makes oral dosing optional, while claim 2 requires it.

Does the patent cover all 100-mg IV omadacycline dosing?

No. The claims require a defined sequence: three 100-mg IV doses 12 hours apart, followed by 100-mg IV dosing every 24 hours.

Can an omadacycline generic avoid this patent by changing the loading schedule?

Potentially, but changing the loading schedule would not resolve exposure under other patents or eliminate regulatory and induced-infringement issues.

Is a biosimilar application required for a competing omadacycline product?

No. Omadacycline is a small-molecule antibacterial. A competing product would generally use the ANDA pathway, not the biosimilar pathway under the Biologics Price Competition and Innovation Act.

References

United States Patent and Trademark Office. (2019). US Patent No. 10,383,884, methods of treating community-acquired bacterial pneumonia. https://patents.google.com/patent/US10383884B2/en
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book patent data. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
U.S. Food and Drug Administration. (2018). FDA approves new antibiotic to treat serious bacterial infections. https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-treat-serious-bacterial-infections
U.S. Food and Drug Administration. (2023). Nuzyra (omadacycline) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209816s011,209817s010lbl.pdf

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Paratek Pharms	NUZYRA	omadacycline tosylate	POWDER;INTRAVENOUS	209817-001	Oct 2, 2018		RX	Yes	Yes	10,383,884	⤷ Start Trial				TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA	⤷ Start Trial
Paratek Pharms	NUZYRA	omadacycline tosylate	TABLET;ORAL	209816-001	Oct 2, 2018		RX	Yes	Yes	10,383,884	⤷ Start Trial				TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017353588	⤷ Start Trial
Brazil	112019008897	⤷ Start Trial
Canada	3042514	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,383,884

Which drugs does patent 10,383,884 protect, and when does it expire?

Summary for Patent: 10,383,884